4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Has Average Price Target of $28.90

Key Points

• Analysts maintain a “Moderate Buy” consensus on 4D Molecular Therapeutics, with 10 buy ratings, one hold, and one sell. The average 12-month price target is $28.90, substantially above the stock’s reported $13.00 opening price.
• The company reported a quarterly loss of $1.04 per share, slightly worse than the expected $1.02 loss, while revenue of $3.78 million exceeded estimates of $3.62 million. Analysts forecast a full-year loss of $4.14 per share.
• Institutional investors own 99.27% of FDMT, while insiders have recently sold shares, including 134,570 shares valued at approximately $1.76 million over the past three months.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has received an average rating of "Moderate Buy" from the twelve brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $28.90.

Several research firms recently issued reports on FDMT. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. B. Riley Financial reaffirmed a "buy" rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Finally, Bank of America lifted their price objective on shares of 4D Molecular Therapeutics from $29.00 to $33.00 and gave the stock a "buy" rating in a research note on Tuesday, September 29th.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $13.00 on Tuesday. The stock has a market capitalization of $718.12 million, a PE ratio of -4.94 and a beta of 2.75. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics has a 12-month low of $6.96 and a 12-month high of $16.93. The stock's 50 day simple moving average is $13.84 and its 200 day simple moving average is $11.45.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. The company had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, research analysts forecast that 4D Molecular Therapeutics will post -4.14 earnings per share for the current fiscal year.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, insider David Kirn sold 58,333 shares of the firm's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $12.92, for a total transaction of $753,662.36. Following the transaction, the insider owned 709,153 shares in the company, valued at approximately $9,162,256.76. This trade represents a 7.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders sold 134,570 shares of company stock valued at $1,759,323. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in FDMT. Toth Financial Advisory Corp purchased a new stake in shares of 4D Molecular Therapeutics during the third quarter worth about $29,000. Opaleye Management Inc. raised its position in shares of 4D Molecular Therapeutics by 197.8% in the 2nd quarter. Opaleye Management Inc. now owns 334,437 shares of the company's stock valued at $4,448,000 after purchasing an additional 222,146 shares during the last quarter. Engineers Gate Manager LP raised its position in shares of 4D Molecular Therapeutics by 132.0% in the 2nd quarter. Engineers Gate Manager LP now owns 68,206 shares of the company's stock valued at $907,000 after purchasing an additional 38,806 shares during the last quarter. AXQ Capital LP acquired a new stake in 4D Molecular Therapeutics in the 2nd quarter worth approximately $186,000. Finally, Headlands Technologies LLC boosted its stake in 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company's stock worth $256,000 after purchasing an additional 3,282 shares in the last quarter. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company uses its Therapeutic Vector Evolution platform to engineer adeno-associated virus (AAV) vectors designed to deliver genetic medicines to specific tissues, including the eye and lungs.

Its investigational pipeline includes 4D-150, an intravitreal gene therapy being developed for retinal diseases such as wet age-related macular degeneration and diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.